Joseph Gardner
PhD - President and Founder
Dr. Gardner was the founding CEO of Akebia Therapeutics, Inc. in 2007, following twenty-three years of pharmaceutical discovery and development work at Procter & Gamble Pharmaceuticals. As CEO of Akebia, Read More
Stephen Hoffman
MD, PhD – Chief Executive Officer
Dr. Hoffman joins Aerpio Pharmaceuticals from PDL BioPharma, an investment firm that manages a portfolio of investments in companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and Read More
Kevin Peters
MD - Chief Scientific Officer
Dr. Peters guided the early preclinical and clinical development of AKB-9778 while at Akebia and Aerpio, and currently leads scientific discovery and translational development for Aerpio. He was formerly the Read More
Steve Pakola
MD - Chief Medical Officer
Dr. Steve Pakola is a licensed physician with over 20 years of biopharmaceutical experience, including over 15 years as a Chief Medical Officer for ophthalmology-focused companies. He has played leadership Read More
Michael Rogers
Chief Financial Officer
Mr. Rogers has more than 25 years of experience in the biopharmaceutical industry, serving as Chief Financial Officer (CFO) of five publicly-traded healthcare companies. He most recently served as CFO Read More
Dhaval Desai
PharmD - Vice-President, Medical Affairs
Dhaval comes to Aerpio with 15 years of experience in marketing, medical affairs and clinical development. In addition, he brings hands-on pre- and post-launch experience in the retina therapeutic space. Read More
Mitchell Brigell
PhD - Vice-President, Clinical Development
Prior to joining Aerpio in 2013, Dr. Brigell was Executive Director of Translational Medicine, Ophthalmology at Novartis Institutes of BioMedical Research and held roles of increasing responsibility at Parke-Davis/Pfizer in Read More
Brandi Soldo
PhD, DABT – Vice-President, Toxicology
Brandi is a diplomat of the American Board of Toxicology with 18 years of nonclinical toxicology experience. Dr. Soldo leads nonclinical exploratory safety/PK and GLP IND-enabling through Phase 3-support ADME, Read More